

Daniel C Malone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4792538/publications.pdf>

Version: 2024-02-01

89
papers

2,810
citations

249298

26
h-index

214428

50
g-index

95
all docs

95
docs citations

95
times ranked

3594
citing authors

#	ARTICLE	IF	CITATIONS
1	Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. <i>Health Policy</i> , 2022, 126, 49-59.	1.4	7
2	The potential for leveraging machine learning to filter medication alerts. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 891-899.	2.2	10
3	Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300) Tj ETQq1 1 0.784314 rgBT /Over Pharmacy. 2022. . 1-12.	0.5	3
4	Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. <i>Addiction</i> , 2022, 117, 2254-2263.	1.7	2
5	Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. <i>Pharmacogenomics Journal</i> , 2022, 22, 188-197.	0.9	4
6	Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S.. <i>American Journal of Emergency Medicine</i> , 2022, 55, 147-151.	0.7	2
7	Coordinated use of Health Level 7 standards to support clinical decision support: Case study with shared decision making and drug-drug interactions. <i>International Journal of Medical Informatics</i> , 2022, 162, 104749.	1.6	5
8	Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
9	Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. <i>Advances in Therapy</i> , 2022, 39, 3678-3695.	1.3	3
10	Overriding Drug-Drug Interaction Alerts in Clinical Decision Support Systems: A Scoping Review. <i>Studies in Health Technology and Informatics</i> , 2022, , .	0.2	3
11	Dual-trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study. <i>Addiction</i> , 2021, 116, 819-830.	1.7	26
12	Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 421-431.	1.0	13
13	An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1889841.	0.8	27
14	Effectiveness and Efficiency of Non-drug Therapy Among Community-Dwelling Adults With Hypertension in China: A Protocol for Network Meta-Analysis and Cost-Effectiveness Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 651559.	1.2	5
15	Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder. <i>Postgraduate Medicine</i> , 2021, 133, 421-427.	0.9	10
16	A Shared Decision-making Tool for Drug Interactions Between Warfarin and Nonsteroidal Anti-inflammatory Drugs: Design and Usability Study. <i>JMIR Human Factors</i> , 2021, 8, e28618.	1.0	5
17	Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial. <i>JMIR Medical Informatics</i> , 2021, 9, e24359.	1.3	13
18	Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 2245-2255.	0.5	5

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 948-960.	0.5	0
20	Payer perceptions of the use of real-world evidence in oncology-based decision making. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1096-1105.	0.5	6
21	Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder. <i>Hospital Practice (1995)</i> , 2021, 49, 348-355.	0.5	11
22	The lifetime cost estimation of human papillomavirus-related diseases in China: a modeling study. <i>Journal of Translational Internal Medicine</i> , 2021, 9, 200-211.	1.0	7
23	Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. <i>Journal of General Internal Medicine</i> , 2021, 36, 908-915.	1.3	4
24	Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1966187.	0.8	6
25	Value of Active Warming Devices for Intraoperative Hypothermia Prevention—A Meta-Analysis and Cost-Benefit Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11360.	1.2	5
26	Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, , 1-9.	0.7	1
27	Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016. <i>Journal of Clinical Medicine</i> , 2020, 9, 83.	1.0	32
28	Testing the face validity and inter-rater agreement of a simple approach to drug-drug interaction evidence assessment. <i>Journal of Biomedical Informatics</i> , 2020, 101, 103355.	2.5	4
29	Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review. <i>Quality of Life Research</i> , 2020, 29, 593-605.	1.5	19
30	Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. <i>PLoS ONE</i> , 2020, 15, e0235981.	1.1	27
31	<p>Extent and Factors Associated with Adherence to Antidepressant Treatment During Acute and Continuation Phase Depression Treatment Among Older Adults with Dementia and Major Depressive Disorder</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 1433-1450.	1.0	2
32	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. <i>Journal of Market Access & Health Policy</i> , 2020, 8, 1822666.	0.8	18
33	Health Outcomes Associated with Adherence to Antidepressant Use during Acute and Continuation Phases of Depression Treatment among Older Adults with Dementia and Major Depressive Disorder. <i>Journal of Clinical Medicine</i> , 2020, 9, 3358.	1.0	6
34	Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. <i>Current Medical Research and Opinion</i> , 2020, 36, 1619-1626.	0.9	3
35	Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1066-1074.	1.8	25
36	Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. <i>Value in Health</i> , 2020, 23, 409-415.	0.1	23

#	ARTICLE	IF	CITATIONS
37	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. <i>Lancet Oncology</i> , 2020, 21, e83-e96.	5.1	180
38	Evidence of Clinically Meaningful Drug-Drug Interaction With Concomitant Use of Colchicine and Clarithromycin. <i>Drug Safety</i> , 2020, 43, 661-668.	1.4	13
39	Integrating the Practical Robust Implementation and Sustainability Model With Best Practices in Clinical Decision Support Design: Implementation Science Approach. <i>Journal of Medical Internet Research</i> , 2020, 22, e19676.	2.1	23
40	Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 1604-1611.	0.5	4
41	Title is missing!. , 2020, 15, e0235981.		0
42	Title is missing!. , 2020, 15, e0235981.		0
43	Title is missing!. , 2020, 15, e0235981.		0
44	Title is missing!. , 2020, 15, e0235981.		0
45	Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 294-302.	1.8	22
46	Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015. <i>Value in Health</i> , 2019, 22, 871-877.	0.1	2
47	Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. <i>Journal of Market Access & Health Policy</i> , 2019, 7, 1601484.	0.8	62
48	Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. <i>JAMA Network Open</i> , 2019, 2, e190968.	2.8	134
49	Extent and Predictors of Potentially Inappropriate Antidepressant Use Among Older Adults With Dementia and Major Depressive Disorder. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 794-805.	0.6	8
50	Clinician preferences for computerised clinical decision support for medications in primary care: a focus group study. <i>BMJ Health and Care Informatics</i> , 2019, 26, e000015.	1.4	36
51	Identifying Common Methods Used by Drug Interaction Experts for Finding Evidence About Potential Drug-Drug Interactions: Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2019, 21, e11182.	2.1	15
52	Implementation of Clinical Decision Support Services to Detect Potential Drug-Drug Interaction Using Clinical Quality Language. <i>Studies in Health Technology and Informatics</i> , 2019, 264, 724-728.	0.2	12
53	Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries. <i>Epilepsy and Behavior</i> , 2018, 80, 208-214.	0.9	18
54	An update on the prevalence and incidence of epilepsy among older adults. <i>Epilepsy Research</i> , 2018, 139, 107-112.	0.8	29

#	ARTICLE	IF	CITATIONS
55	Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?. <i>Value in Health</i> , 2018, 21, 326-333.	0.1	46
56	Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing. <i>Journal of Medical Economics</i> , 2018, 21, 326-339.	1.0	17
57	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. <i>Lancet Oncology</i> , The, 2018, 19, e459-e469.	5.1	66
58	Are US Health Insurers Efficient or Not?. <i>Value in Health</i> , 2018, 21, 398-399.	0.1	1
59	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. <i>Clinical Trials</i> , 2018, 15, 624-630.	0.7	42
60	Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 613-620.	0.5	16
61	Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. <i>PLoS ONE</i> , 2016, 11, e0164972.	1.1	68
62	Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma. <i>American Journal of Ophthalmology</i> , 2016, 168, 78-85.	1.7	10
63	Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study. <i>Therapeutic Advances in Chronic Disease</i> , 2016, 7, 220-228.	1.1	11
64	The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis. <i>Neurourology and Urodynamics</i> , 2016, 35, 48-54.	0.8	35
65	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. <i>Lancet Oncology</i> , The, 2016, 17, e510-e514.	5.1	158
66	Predictive modeling using a nationally representative database to identify patients at risk of developing microalbuminuria. <i>International Urology and Nephrology</i> , 2016, 48, 249-256.	0.6	2
67	Consensus Recommendations for Systematic Evaluation of Drug-Drug Interaction Evidence for Clinical Decision Support. <i>Drug Safety</i> , 2015, 38, 197-206.	1.4	96
68	Recommendations to improve the usability of drug-drug interaction clinical decision support alerts. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1243-1250.	2.2	154
69	Towards a foundational representation of potential drug-drug interaction knowledge. <i>CEUR Workshop Proceedings</i> , 2014, 1309, 16-31.	2.3	3
70	Effect of an Educational Outreach Program on Prescribing Potential Drug-Drug Interactions. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 549-557.	2.2	10
71	Evaluation of a Wireless Handheld Medication Management Device in the Prevention of Drug-Drug Interactions in a Medicaid Population. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 33-45.	2.2	12
72	Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 32-37.	2.2	108

#	ARTICLE	IF	CITATIONS
73	Burden of Alzheimer's disease and association with negative health outcomes. American Journal of Managed Care, 2009, 15, 481-8.	0.8	35
74	Pharmacist Workload and Pharmacy Characteristics Associated With the Dispensing of Potentially Clinically Important Drug-Drug Interactions. Medical Care, 2007, 45, 456-462.	1.1	98
75	Assessment of potential drug-drug interactions with a prescription claims database. American Journal of Health-System Pharmacy, 2005, 62, 1983-1991.	0.5	104
76	Concordance of Severity Ratings Provided in Four Drug Interaction Compendia. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 136-141.	0.7	165
77	Identification of Serious Drug-Drug Interactions: Results of the Partnership to Prevent Drug-Drug Interactions. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 142-151.	0.7	155
78	Interpreting the findings of the IMPROVE study. American Journal of Health-System Pharmacy, 2001, 58, 1330-1337.	0.5	42
79	Reduced Quality of Life in Veterans at Risk for Drug-Related Problems. Pharmacotherapy, 2001, 21, 1123-1129.	1.2	9
80	Economic burden of asthma: implications for outcomes and cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2001, 1, 177-186.	0.7	3
81	The Relationship between Drug Therapy Noncompliance and Patient Characteristics, Health-Related Quality of Life, and Health Care Costs. Pharmacotherapy, 2000, 20, 941-949.	1.2	102
82	An Economic Analysis of a Randomized, Controlled, Multicenter Study of Clinical Pharmacist Interventions for High-Risk Veterans: The IMPROVE Study. Pharmacotherapy, 2000, 20, 1149-1158.	1.2	74
83	Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study. Pharmacotherapy, 2000, 20, 1508-1516.	1.2	125
84	Types of Interventions Made by Clinical Pharmacists in the IMPROVE Study. Pharmacotherapy, 2000, 20, 429-435.	1.2	49
85	Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers. American Journal of Health-System Pharmacy, 2000, 57, 29-39.	0.5	31
86	Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers. American Journal of Health-System Pharmacy, 1998, 55, 68-72.	0.5	28
87	The IMPROVE study: Background and study design. American Journal of Health-System Pharmacy, 1998, 55, 62-67.	0.5	29
88	QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data. Drugs - Real World Outcomes, 0, , .	0.7	0
89	A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Safety, 0, , .	1.4	3